Evidence map›Paper›PMID 40696378›Full record

ReviewMolecular cancer2025

Primary and secondary metastatic dissemination: multiple routes to cancer-related death.

D Sparrer, R Blazquez, F Keil, S Einhell, F Lüke, S Uderhardt, C Gerner, C H R Wendl, M Proescholdt, C Schulz and 12 more

Abstract readReview
In one paragraph

Review in Molecular cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

D SparrerCenter for Translational Oncology, University Hospital Regensburg, Regensburg, 93053, Germany.
R BlazquezDepartment of Internal Medicine III, University Hospital Regensburg, Regensburg, 93053, Germany.
F KeilInstitute of Pathology, University of Regensburg, Regensburg, 93053, Germany.
S EinhellDepartment of Internal Medicine III, University Hospital Regensburg, Regensburg, 93053, Germany.
F LükeCenter for Translational Oncology, University Hospital Regensburg, Regensburg, 93053, Germany.
S UderhardtDepartment of Medicine 3 - Rheumatology and Immunology, University Hospital Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, 91054, Germany.
C GernerDepartment of Analytical Chemistry, Faculty of Chemistry, University of Vienna, Waehringer Str. 38, Vienna, 1090, Austria.
C H R WendlInstitute of Radiology, University Hospital Regensburg, Regensburg, 93053, Germany.
M ProescholdtDepartment of Neurosurgery, University Hospital Regensburg, Regensburg, 93053, Germany.
C SchulzBavarian Cancer Research Center (BZKF), Germany, 93053, Regensburg.
A KandulskiDepartment of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology and Infectious Diseases, University Hospital Regensburg, Regensburg, 93053, Germany.
S HaferkampDepartment of Dermatology, University Hospital Regensburg, Regensburg, 93053, Germany.
H J SchlittBavarian Cancer Research Center (BZKF), Germany, 93053, Regensburg.
T BäuerlePreclinical Imaging Platform Erlangen, Institute of Radiology, University Hospital Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Palmsanlage 5, Erlangen, 91054, Germany.
K FranzeDepartment of Physiology, Development and Neuroscience, University of Cambridge, Downing Street, Cambridge, CB2 3DY, UK.
R MayrDepartment of Urology, Caritas St. Josef Hospital, University of Regensburg, Regensburg, 93053, Germany.
M RechenmacherDepartment of Internal Medicine III, University Hospital Regensburg, Regensburg, 93053, Germany.
P HauDepartment of Neurology and Wilhelm Sander Neuro-Oncology Unit, University Hospital Regensburg, Regensburg, 93053, Germany.
D HirschInstitute of Pathology, University of Regensburg, Regensburg, 93053, Germany.
D HeudoblerCenter for Translational Oncology, University Hospital Regensburg, Regensburg, 93053, Germany.
K EvertInstitute of Pathology, University of Regensburg, Regensburg, 93053, Germany.
T PukropCenter for Translational Oncology, University Hospital Regensburg, Regensburg, 93053, Germany. tobias.pukrop@klinik.uni-regensburg.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metastatic disease accounts for approximately 80% of cancer-related deaths, typically manifesting as single-organ failure mainly through abdominal, cardiovascular, neurological, or respiratory complications. Despite treating thousands of cancer patients daily worldwide, our understanding of organ-specific metastatic dissemination routes, tissue destruction mechanisms and reasons for organ failures remains limited. As cancer-directed therapies advance, maintaining organ function has emerged as a critical therapeutic goal of care. To develop more effective treatment strategies, a comprehensive understanding of the pathophysiology is essential, particularly regarding secondary and subsequent metastatic waves that lead to extensive macro-metastases and organ failure. Critical distinction between primary metastatic spread and secondary intra-organ dissemination is crucial. In the era of precision oncology, elucidating organ-specific destruction processes and the pathophysiology of metastatic waves is fundamental for advancing patient care. To highlight the emerging goal of care of maintaining organ function, we aligned the metastatic biology, clinical stages, goals of care and therapeutic indications: the Bio Therapeutic Goals of Cancer Care Model.

Indexed as

NeoplasmsAnimalsHumansNeoplasm MetastasisBio Therapeutic Goals of Cancer Care ModelCancer-directed therapyCNSMetastasisMetastatic disseminationPrimary disseminationSecondary dissemination

Identifiers

PMID40696378
PMCPMC12281838

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.